BNP Paribas Financial Markets’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$112K Sell
24,317
-3,308
-12% -$12.5K ﹤0.01% 4486
2026
Q1
$79.8K Buy
27,625
+26,931
+3,881% +$57.4K ﹤0.01% 4481
2025
Q4
$1.12K Sell
694
-85,977
-99% -$135K ﹤0.01% 5394
2025
Q3
$146K Buy
86,671
+40,539
+88% +$65.6K ﹤0.01% 4149
2025
Q2
$55.8K Sell
46,132
-59,011
-56% -$85.6K ﹤0.01% 4219
2025
Q1
$134K Buy
105,143
+12,284
+13% +$32.1K ﹤0.01% 3923
2024
Q4
$302K Buy
92,859
+2,080
+2% +$7.49K ﹤0.01% 3630
2024
Q3
$299K Buy
90,779
+71,643
+374% +$279K ﹤0.01% 3077
2024
Q2
$81.3K Sell
19,136
-16,177
-46% -$158K ﹤0.01% 3346
2024
Q1
$520K Sell
35,313
-6,796
-16% -$103K ﹤0.01% 2823
2023
Q4
$405K Buy
42,109
+24,883
+144% +$172K ﹤0.01% 2911
2023
Q3
$80.3K Sell
17,226
-12,446
-42% -$62K ﹤0.01% 3379
2023
Q2
$159K Sell
29,672
-12,068
-29% -$74.4K ﹤0.01% 3095
2023
Q1
$299K Sell
41,740
-38,019
-48% -$229K ﹤0.01% 2983
2022
Q4
$535K Buy
79,759
+14,414
+22% +$79K ﹤0.01% 2531
2022
Q3
$226K Sell
65,345
-23,585
-27% -$90.2K ﹤0.01% 3433
2022
Q2
$262K Buy
88,930
+6,989
+9% +$36.7K ﹤0.01% 2973
2022
Q1
$722K Buy
81,941
+2,841
+4% +$31.4K ﹤0.01% 2535
2021
Q4
$1.27M Buy
79,100
+68,425
+641% +$1.29M ﹤0.01% 2422
2021
Q3
$224K Buy
10,675
+8,499
+391% +$205K ﹤0.01% 2996
2021
Q2
$58.4K Sell
2,176
-4,844
-69% -$142K ﹤0.01% 3209
2021
Q1
$224K Buy
7,020
+108
+2% +$2.62K ﹤0.01% 2990
2020
Q4
$158K Sell
6,912
-5,544
-45% -$128K ﹤0.01% 2992
2020
Q3
$314K Buy
12,456
+9,541
+327% +$261K ﹤0.01% 2483
2020
Q2
$81.4K Sell
2,915
-20,701
-88% -$360K ﹤0.01% 2852
2020
Q1
$137K Buy
23,616
+18,059
+325% +$164K ﹤0.01% 3053
2019
Q4
$60.5K Sell
5,557
-1,818
-25% -$18K ﹤0.01% 3536
2019
Q3
$94.1K Buy
7,375
+2,996
+68% +$43.1K ﹤0.01% 3153
2019
Q2
$74.3K Sell
4,379
-3,780
-46% -$64.9K ﹤0.01% 3200
2019
Q1
$147K Buy
8,159
+8,146
+62,662% +$141K ﹤0.01% 2885
2018
Q4
$165 Sell
13
-1,320
-99% -$22.1K ﹤0.01% 4124
2018
Q3
$28.6K Hold
1,333
﹤0.01% 3268
2018
Q2
$27.5K Sell
1,333
-5,903
-82% -$133K ﹤0.01% 3369
2018
Q1
$182K Buy
7,236
+216
+3% +$5.25K ﹤0.01% 2844
2017
Q4
$133K Buy
7,020
+3,674
+110% +$68.6K ﹤0.01% 3153
2017
Q3
$61.8K Sell
3,346
-237
-7% -$4.11K ﹤0.01% 3036
2017
Q2
$62.7K Buy
3,583
+3,348
+1,425% +$63.9K ﹤0.01% 3068
2017
Q1
$4.37K Sell
235
-356
-60% -$6.87K ﹤0.01% 3344
2016
Q4
$12.1K Sell
591
-1,617
-73% -$40.7K ﹤0.01% 3367
2016
Q3
$66K Buy
2,208
+976
+79% +$29K ﹤0.01% 2307
2016
Q2
$33.3K Buy
+1,232
New +$27.8K ﹤0.01% 2428
2016
Q1
Sell
-6,256
Closed -$194K 2913
2015
Q4
$194K Sell
6,256
-436
-7% -$13.2K ﹤0.01% 1949
2015
Q3
$143K Buy
6,692
+4,352
+186% +$137K ﹤0.01% 2174
2015
Q2
$88.8K Buy
2,340
+1,865
+393% +$61.3K ﹤0.01% 2141
2015
Q1
$14.9K Buy
+475
New +$16.1K ﹤0.01% 2524
2014
Q4
Sell
-1,127
Closed -$23.6K 2704
2014
Q3
$23.6K Buy
+1,127
New +$23.3K ﹤0.01% 3063
2014
Q1
Sell
-70
Closed -$1.92K 3642
2013
Q4
$1.92K Buy
+70
New +$1.83K ﹤0.01% 3675

Other funds holding MGNX

BNP Paribas Financial Markets's MGNX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its MacroGenics (MGNX) stake by 12% in Q2 2026, selling an estimated $12.5K and leaving 24,317 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #4486.

BNP Paribas Financial Markets first reported a position in MGNX in Q4 2013 and has held it in 47 quarters since. The position peaked at $1.27M in Q4 2021. 112 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • BNP Paribas Financial Markets held 24,317 shares of MacroGenics worth $112K as of Q2 2026.
  • BNP Paribas Financial Markets sold 3,308 MacroGenics shares in Q2 2026, an estimated $12.5K.
  • MacroGenics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4486 holding.
  • BNP Paribas Financial Markets first reported a position in MacroGenics in Q4 2013 and has held it in 47 quarters since.
  • BNP Paribas Financial Markets's MacroGenics position peaked at $1.27M in Q4 2021.
  • 112 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.